FMP
Enter
API Tools
Extras
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
WACOC
Price
2.01
Beta
Diluted Shares Outstanding
1.23M
Costof Debt
4.04
Tax Rate
After Tax Cost Of Debt
4.04
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
0
Total Equity
2.47M
Total Capital
2.47M
Debt Weighting
0
Equity Weighting
100
Wacc
4.98
